| ¿µ¹® | epidemiology, reflux | ÇÑ±Û | ¿ªÇÐ |
|---|---|---|---|
| ¼³¸í | ¾î¶² Áö¿ªÀ̳ª Áý´Ü ¾È¿¡¼ ÀϾ´Â Áúº´ÀÇ ¿øÀÎÀ̳ª º¯µ¿ »óŸ¦ ¿¬±¸ÇÏ´Â Çй®. Àü¿°º´ÀÇ ¹ß»ý, À¯Çà, Á¾½Ä¿¡ ¹ÌÄ¡´Â Á¶°ÇÀ» ¹àÇô Àü¿°º´ÀÇ ¿¹¹æ°ú Ä¡·á¸¦ ¿¬±¸ÇÏ´Â °Í¿¡¼ ½ÃÀÛÇÏ¿© ÇöÀç´Â ÀçÇØ³ª °øÇØ µûÀ§ÀÇ ¹®Á¦µµ ´Ù·é´Ù. |
||
| ¿µ¹® | genetic engineering | ÇÑ±Û | À¯Àü°øÇÐ |
|---|---|---|---|
| ¼³¸í | 1. À¯ÀüÀÚÀÇ ÇÕ¼ºÀ̳ª º¯Çü µûÀ§¸¦ ¿¬±¸ÇÏ´Â Çй®. ÀÀ¿ë À¯ÀüÇÐÀÇ ÇÑ ºÐ¾ß·Î, º´ÀÇ Ä¡·á³ª ÀÌ·Î¿î »ê¹°ÀÇ ´ë·® »ý»êÀ» ¸ñÀûÀ¸·Î ÇÑ´Ù. 2. »ý¹°ÀÇ À¯ÀüÀÚ¸¦ ÀΰøÀûÀ¸·Î °¡°øÇÏ¿© Àΰ£¿¡°Ô ÇÊ¿äÇÑ ¹°ÁúÀ» ´ë·®À¸·Î °ª½Î°Ô ¾ò´Â ±â¼ú. 1970³â´ë¿¡ µé¾î¼¸é¼ °æÀÌÀûÀÎ °úÇбâ¼úÀÇ Çϳª·Î Å« ÁÖ¸ñÀ» ²ø°í ÀÖÀ¸¸ç, ÀÌ ºÐ¾ß¿¡´Â ÀçÁ¶ÇÕ DNA±â¼ú-¼¼Æ÷À¶ÇÕ±â¼ú ¹× ÇÙġȯ±â¼ú µîÀÌ ÀÖ´Ù. ÀçÁ¶ÇÕ DNA ±â¼ú¿¡ ÀÇÇÏ¿© ÀΰøÀûÀ¸·Î ÀçÁ¶ÇÕÀ¯ÀüÀÚ¸¦ ¸¸µç ÃÖÃÊÀÇ º¸°í´Â 1972³â Àè½¼ µîÀÌ ÇÏ¿´°í, ÀΰøÀû ÀçÁ¶ÇÕÀ¯ÀüÀÚ¸¦ ¼÷ÁÖ¼¼Æ÷¿¡¼ ÇüÁúÀ» ¹ßÇö½ÃŰ´Â µ¥ ÃÖÃÊ·Î ¼º°øÇÑ °ÍÀº 1973³â F. J. ÄÚº¥ µîÀÌ´Ù. ÀÌ ÀçÁ¶ÇÕ DNA ±â¼úÀº ¼¼±ÕÆÄÁö, Çö󽺹̵忡 °üÇÑ ¿¬±¸¿Í DNA¿¡ ÀÛ¿ëÇÏ´Â È¿¼Òµé, ƯÈ÷ Á¦ÇÑÈ¿¼Ò¿Í DNA ¿¬°áÈ¿¼Ò¿¡ °üÇÑ ¿¬±¸¿¡ ÀÇÁ¸ÇÏ¿´´Ù. À¯Àü°øÇÐÀÇ ¹ßÀüÀº ¿ì¸® ¼¼°è¸¦ ¹Ù²Ü ¼ö ÀÖÀ» °ÍÀ¸·Î ³»´Ùº¸°í ÀÖ´Ù. ¾ÏÀ» Á¦¾ÐÇÏ°í ³ëȸ¦ ¹æÁöÇÒ ¼ö ÀÖ¾î À¯Àü°øÇÐÀº °á±¹ ¿À´ÃÀÇ Àΰ£ÀÌ ¾È°í ÀÖ´Â ¿¡³ÊÁö-½Ä·®-ÀÇ·á µîÀÇ ¹®Á¦¸¦ ÇØ°áÇØ ÁÙ ¼ö ÀÖ´Â °¡´É¼ºÀ» Áö´Ñ´Ù. ÀÌ ¶§¹®¿¡ À¯Àü°øÇÐÀº ¡®Á¦3ÀÇ »ê¾÷Çõ¸í¡¯À̶ó°í ÇÒ ¼ö ÀÖ°í, µû¶ó¼ ±× °³¹ßÀ» À§ÇÏ¿© ¿Â ¼¼°èÀÇ ±â¾÷µéÀÌ ÀÌÀÇ ¿¬±¸°³¹ß¿¡ Âø¼öÇÏ°í ±¹°¡µéµµ Àü·«±â¼ú·Î ´Ù·ç¾î ÁýÁ¢ À°¼º¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ´Ù. ¿ì¸®³ª¶ó¿¡¼µµ 1982³âºÎÅÍ À¯Àü°øÇÐ ºÐ¾ß¸¦ ±¹°¡°¡ À°¼ºÇØ¾ß ÇÒ Æ¯Á¤¿¬±¸ ºÐ¾ß·Î ÁöÁ¤Çϰí ÀÖ´Ù. |
||
| ¿µ¹® | genetic code | ÇÑ±Û | À¯ÀüºÎÈ£ |
|---|---|---|---|
| ¼³¸í | ±æ°Ô ´Ã¾î¼ ÀÖ´Â DNA»ç½½ÀÇ À¯ÀüÁ¤º¸°¡ °¢°¢ÀÇ ¾Æ¹Ì³ë»ê¿¡ ´ëÀÀÇÏ¿© ´Ü¹éÁúÀÇ ÇÕ¼º¿¡ »ç¿ëµÉ ¼ö ÀÖ°Ô ÀÐÇôÁö´Â ¹æ¹ý. DNA ºÐÀÚ´Â °¢°¢ÀÇ Deoxyribonucleotide°¡ ¿¬°áµÇ¾î¼ ÀÌ·ç´Â ±¸Á¶ÀÌ´Ù. ÀÌDeoxyribonucleolide´Â ´ç, Àλê, ±×¸®°í ¿°±â·Î ÀÌ·ç¾îÁ® ÀÖ´Ù. ´ç°ú ÀλêÀº °¢°¢ÀÇ Deoxyribonucleotide°¡ ¿¬°áµÇ°Ô À¯ÁöÇØÁÖ´Â ¿ªÇÒÀ» ÇÏ°í ¿°±â°¡ À¯ÀüÁ¤º¸¸¦ °¡Áö°í ÀÖÀ¸¸ç ÀÌ ¿°±âÀÇ ¹è¿ÀÌ À¯ÀüÁ¤º¸ Áï ´Ü¹éÁúÀÇ ÇÕ¼º¿¡ ÇÊ¿äÇÑ Á¤º¸¸¦ °¡Áö°í ÀÖ´Ù. DNA¸¦ ÀÌ·ç´Â ¿°±â´Â 4°³·Î ¾Æµ¥´Ñ(adenine), ±¸¾Æ´Ñ(guanine), Ƽ¹Î(thymine), ½ÃÅä½Å(cytosine)ÀÇ 4°¡ÁöÀÌ´Ù. 4°³ÀÇ ¿°±â°¡ ¼¯¿©ÀÖ´Â ¹è¿À» ÇÑ °³ÀÇ ´Ü¹éÁú·Î ÇÕ¼ºÀ» Çϱâ À§Çؼ´Â ÀÌ ¹è¿À» ÇØµ¶ÇÏ´Â ¹æ¹ýÀÌ ÀÖ¾î¾ß ÇÑ´Ù. Áï ±× ¹æ¹ýÀº 3°³ÀÇ ¿°±âÀÇ ¹è¿À» ÇϳªÀÇ ¾Æ¹Ì³ë»ê¿¡ ´ëÀÀ½ÃÄѼ °¢ ¾Æ¹Ì³ë»êÀÇ ¼¿À» Á¤ÇÏ°í ´Ü¹éÁúÀ» ¸¸µå´Â °ÍÀÌ´Ù. ¿¹¸¦ µé¸é cytosine-cytosine-cytosineÀ̶ó´Â ¹è¿Àº prolineÀ̶ó´Â ´Ü¹éÁúÀ» ÀǹÌÇÏ´Â °ÍÀ¸·Î ÀÐÇôÁö°Ô µÈ´Ù. ÀÌ·¸°Ô ¾Æ¹«·± ±ÔÄ¢ÀÌ ¾ø´Â °Í °°Àº ¿°±â¼¿À» ÇϳªÀÇ ¾Æ¹Ì³ë»ê°ú ´ëÀÀ½ÃÄѼ Àд ¹æ¹ýÀÌ À¯ÀüºÎÈ£ÀÌ´Ù. |
||
| EPDML | epidemiology, epidemiologic |
|---|---|
| GREPCO | Rome Group for the Epidemiology and Prevention of Cholelithiasis |
| PERI | Psychiatric Epidemiology Research Interview |
| SEER | Surveillance Epidemiology and End Results [Program] |
| CuS | copper supplement |
| ECGS | Endothelial Cell Growth Supplement |
|---|---|
| ABLES | Adult Blood Lead Epidemiology and Surveillance program |
| EDC | Epidemiology of Diabetes Complications |
| SEER | Surveillance Epidemiology and End Results |
| SEER | Surveillance, Epidemiology and End Results Program |
| supplement | Something that supplies a want or make an addition: something that completes, adds a finishing touch or brings closer to completion or a desired state. (18 Nov 1997) |
|---|---|
| classical epidemiology | <epidemiology> Our term for the varieties of epidemiology primarily concerned with the statistical relationships between disease agents, both infectious and non-infectious; for example a study to establish the relative risk of lung cancer associated with smoking. We contrast this with ecological epidemiology. (05 Dec 1998) |
| clinical epidemiology | The field concerned with applying epidemiological principles in a clinical setting.Whereas classical epidemiology studies populations in an attempt to assess causes and distribution of disease and to formulate statistical measures of risk, clinical epidemiology focuses on medically defined populations (patients). (05 Mar 2000) |
| ecological epidemiology | <epidemiology> A branch of epidemiology which views disease as a result of the ecological interactions between populations of hosts and parasites; what we do. We contrast this with classical epidemiology. (05 Dec 1998) |
| epidemiology | <study> The study of the distribution and determinants of health-related states and events in populations and the control of health problems, the study of epidemic disease. (27 Sep 1997) |
| epidemiology, classical | The study of populations in order to determine the frequency and distribution of disease and measure risks. (12 Dec 1998) |
| epidemiology, clinical | Epidemiology focused specifically upon patients. (12 Dec 1998) |
| epidemiology, molecular | The application of molecular biology to the answering of epidemiological questions. The examination of patterns of changes in DNA to implicate particular carcinogens and the use of molecular markers to predict which individuals are at highest risk for a disease are common examples. (12 Dec 1998) |
| genetic | <biology> Pertaining to reproduction or to birth or origin. (07 May 1998) |
| genetic amplification | A process for producing an increase in pertinent genetic material, particularly for increasing the proportion of plasmid DNA to that of bacterial DNA. Includes the production of extrachromosomal copies of the genes for RNA. (05 Mar 2000) |
| genetic assimilation | <genetics> A situation in which a characteristic that is normally expressed only in certain environmental situations becomes fixed in a population so that it no longer requires environmental factors to be expressed. (07 May 1998) |
| genetic association | The occurrence together in a population, more often than can be readily explained by chance, of two or more traits of which at least one is known to be genetic. (05 Mar 2000) |
| genetic block | <biochemistry, molecular biology> An obstruction in a biochemical pathway caused by a mutation that has crippled production of an enzyme critical to the pathway. (07 May 1998) |
| genetic burden | The genetic debt due to harmful mutation but as yet undischarged. (In a large population of fixed size every mutation with diminished genetic fitness will eventually become extinct and depending on the details of inheritance and phenotype must be paid for by a fixed number of genetic deaths per mutation, the genetic debt.) (05 Mar 2000) |
| genetic carrier | An unaffected heterozygote bearing a usually harmful recessive gene, a cancer that bears a dominant but latent age-dependent trait to have offspring with unbalanced karyotypes. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|